LEMAITRE VASCULAR, INC. (LMAT) Return on equity 2016–2025
LEMAITRE VASCULAR, INC. (LMAT) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
14.7%FY2025 · since FY2016: 12.1% → 14.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 14.7% | +1.6 pp |
| FY2024 | 13.1% | +3.0 pp |
| FY2023 | 10.1% | +2.4 pp |
| FY2022 | 7.7% | -2.9 pp |
| FY2021 | 10.6% | -1.7 pp |
| FY2020 | 12.3% | +0.2 pp |
| FY2019 | 12.1% | -5.5 pp |
| FY2018 | 17.6% | +2.0 pp |
| FY2017 | 15.6% | +3.5 pp |
| FY2016 | 12.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More LMAT financial trends
LMAT RevenueLMAT Net incomeLMAT Net marginLMAT Gross profitLMAT Gross marginLMAT Operating incomeLMAT Operating marginLMAT Operating cash flowLMAT Free cash flowLMAT Capital expendituresLMAT Stock buybacksLMAT Dividends paidLMAT Total assetsLMAT Total liabilitiesLMAT Shareholders’ equityLMAT overview →